Cipla Limited

Manjinder Singh Phull

Dharmaraj Ramachandra Rao

Rajendra Narayanrao Kankan

Ashwini Amol Sawant

Maruti Ganpati Ghagare

Dilip Ramdas Birari

Geena Malhotra

Manish Gopaldas Gangrade

Srinivas Laxminarayan Pathi

Venkata Srinivas Pullela

Shashirekha Kanathala

Anjaneyaraju Indukari

Geena Malhortra

Muruti Ghagare

Sanoj Thoppil

Sachin Vasant Desai

Dilip Ramda Birari

Ramanaiah Chennuru

Maruti Ghagare

Novel crystalline forms of Bictegravir sodium, pharmaceutical compositions containing said crystalline forms and the use of said crystalline forms in the treatment of HIV infection are disclosed. The present invention is further directed to the processes for the preparation of the novel crystalline forms.

Polymorphs of integrase inhibitor

Amorphous rifaximin, methods of making it, and pharmaceutical compositions containing it. Also described are methods of converting amorphous rifaximin to crystalline rifaximin and vice versa.

Rifaximin

The present invention relates to certain acid salts of (((1-(6-amino-9H-purin-9-yl)propan-2-yloxy)methyl)(phenoxy) phosphoryloxy)methyl pivalate of Formula (I), to processes for their preparation; to pharmaceutical compositions comprising such compounds, and methods of treating a disease which responds to inhibition of nucleotide reverse transcriptase activity.

Salts of antiviral phosphonate analogues and process for preparation thereof

The present application relates to a process for the preparation of piperine of high purity having low concentrations of isomeric impurities.

Process for the preparation of piperine

Amorphous methyl((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl) carbonyl)-2-methylpropyl) carbamate free base, amorphous methyl((1S)-1-(((2S)-2-(5-(4&#x2032;-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl) carbonyl)-2-methylpropyl) carbamate dihydrochloride, methods of making them, and pharmaceutical compositions containing them.

Polymorphic forms of methyl((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate and salts thereof

The present invention provides a compound of the Formula (I) wherein R is 9-isopropyl-9H-purin-6-amine; 2-amino-9-isopropyl-1H-purin-6(9H)-one; 4-amino-1-isopropyl pyrimidin-2(1H)-one; or 1-isopropyl-5-methylpyrimidine-2,4(1H,3H)-dione, R' is &#x2014;CHOC(O)R&#x2033;, and R&#x2033; is &#x2014;C(CH)or &#x2014;CH(CH)including pharmaceutically acceptable salts thereof. The present invention also provides a process for preparing a compound of formula (Ia) and a compound of formula (I) for use in treating a viral infection.

Antiviral phosphonate analogues and process for preparation thereof

In an embodiment, the present invention provides a process for preparing (&#x2212;)-6-(4-aminophenyl)-5-methylpyridazin-3-(2H)-one, which process comprises: a) reacting racemic 6-(4-aminophenyl)-4,5-dihydro-5-methyl-3-(2H)-pyridazinone of formula II with a chiral tartaric acid derivative to obtain a diastereomeric salt of (&#x2212;)-6-(4-aminophenyl)-4,5-dihydro-5-methyl-3-(2H)-pyridazinone and the chiral tartaric acid derivative; and b) reacting the diastereomeric salt with a base to obtain (&#x2212;)-6-(4-aminophenyl)-4,5-dihydro-5-methyl-3-(2H)-pyridazinone. The (&#x2212;)-6-(4-aminophenyl)-4,5-dihydro-5-methyl-3-(2H)-pyridazinone may be used to prepare levosimendan.

Process for preparing levosimendan and intermediates for use in the process

The present invention provides a process for preparing methyl 5-acetamido-4-amino-6-(1,2,3-triacetoxypropyl)-5,6-dihydro-4H-pyran-2-carboxylate (V), which process comprises reducing methyl 5-acetamido-4-azido-6-(1,2,3-triacetoxypropyl)-5,6-dihydro-4H-pyran-2-carboxylate (IV) in the presence of a reducing agent selected from the group consisting of lithium aluminum hydride, sodium borohydride, zinc/ammonium chloride, zinc-ferric chloride and ferric chloride/sodium iodide. The present invention also provides compounds of formula (VIII) and (IX) which may be used in the synthesis of zanamivir. The present invention also provides processes for preparing compounds (VIII) and (IX) and processes involving their use, including in the synthesis of zanamivir. 

Process for preparing zanamivir and intermediates for use in the process

A one-pot process for the preparation of nateglinide, which process comprises reacting an alkyl ester of D-phenylalanine of formula (II):    

Process for the preparation of nateglinide

Crystalline Form C of tenofovir disoproxil, salts thereof and a process for its preparation. The process involves adding a solution comprising tenofovir disoproxil and an organic solvent to salt-saturated water, whereby the crystalline Form C of tenofovir disoproxil precipitates. The crystalline Form C of tenofovir disoproxil may be converted to a salt thereof. There is also provided a process for purifying a crude product comprising tenofovir monoisoproxil and tenofovir disoproxil.

Crystalline form of tenofovir disoproxil and a process for its preparation

The present invention relates to alkaline earth metal salts of bosentan, anyhdrous bosentan, polymorphic forms thereof, amorphous bosentan and processes for preparing them. The present invention further relates to a process for the preparation of bosentan and its pharmaceutically acceptable salts.

Growing community of inventors

Maharashtra, India

Manjinder Singh Phull